TSVT

2seventy bio, Inc. (TSVT) | Rumor.io

2seventy bio

TSVT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about TSVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 13

Insider Kynam Global Healthcare Master Fund, LP sold 16,238,047 shares of $TSVT, valued at $80M.
This trade represents a 100% reduction in the fund's position in 2Seventy Bio, Inc.
The sale was made at $4.93 per share.

Generated by AI

Sentiment

Of the messages about TSVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +43.05
Bearish	—	—	—	0% -43.05

Bullish· Mar 11

$TSVT is being acquired by Bristol Myers Squibb in an all-cash deal valued at approximately $286 million, representing an 88% premium to its current price.
The acquisition is a significant win for biotech bulls, signaling strong value in the sector and driving momentum for the stock.
The deal is expected to provide significant value to shareholders, with the stock price surging over 76% in pre-market trading.

Bearish· Mar 11

$TSVT was acquired by BMS for a low price of $5 per share, with a total deal value of $102M net of cash.
The acquisition is considered a terrible deal for shareholders, with BMS paying only 85% of 1 year of TSVT's sales share.
The combined value of TSVT and BLUE has collapsed, with the two companies being sold for a total of $300M, down from a peak of $9B.

Generated by AI

Topics

Of the messages about TSVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	24%
Announcements	—	—	—	42%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	34%

Analysts· Nov 8

Morgan Stanley initiated coverage on 2seventy bio (TSVT) with an Overweight rating and a price target of $72.
Several analysts have downgraded bluebird bio (TSVT), including Goldman Sachs to Sell with a price target of $10, and Morgan Stanley to Underweight with a price target of $11.
Analysts have also reduced price targets for bluebird bio (TSVT), including Wedbush to $11, Canaccord Genuity to $15, Wells Fargo to $16, Barclays to $13, and Royal Bank of Canada to $14.

Announcements· Mar 11

2seventy bio, Inc. (TSVT) has entered into a definitive agreement to be acquired by Bristol Myers Squibb (BMY) in an all-cash transaction valued at approximately $286 million.
The acquisition price is $5.00 per share, representing an 88% premium to the closing price of $2.66 on March 7, 2025.
The deal is expected to close in the second quarter of 2025, subject to customary closing conditions.

Controversies· Feb 16

bluebird bio, the company behind 2seventy bio's gene therapy, has temporarily suspended its Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease due to a second case of cancer in a patient.
A lawsuit has been filed against bluebird bio and its executives for allegedly violating federal securities laws, citing concerns over the safety of the company's gene therapy.
The temporary suspension of bluebird bio's gene therapy studies and the resulting regulatory scrutiny are expected to negatively impact other companies in the gene therapy space, including 2seventy bio.

Technical Analysis· Dec 10

$TSVT broke out of a descending bear channel and re-tested it as support with a huge expansion bullish engulfing candle, adding to its watch list and looking to buy a low-volume pullback.
$TSVT has crossed its 6-month MA, indicating a potential 10-dollar move from here, and is currently above its 50-day MA, which acted as significant resistance in the past.
A close above $77.47 on the 30-minute chart would confirm a cup and handle setup, while a close above yesterday's high would be a good sign, indicating potential for a reversal.

Generated by AI

Community

Of the messages about TSVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	60.22%
Newcomers	—	—	—	39.78%

Regulars· Apr 5

The FDA has approved Abecma, a treatment for relapsed or refractory multiple myeloma, which is a significant development for 2seventy bio, Inc. ($TSVT) and its partner Bristol Myers Squibb ($BMY).
Analysts estimate $601M in sales for Abecma in 2024, according to LSEG data, which could have a positive impact on $TSVT's stock price.
Some investors are speculating about a potential buyout from Bristol Myers Squibb, with one user expecting a buyout to happen soon.

Newcomers· Mar 18

$TSVT has received a positive FDA Advisory Committee vote for its Abecma treatment, with an 8-3 vote in favor of its favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma.
2seventy bio, the parent company of $TSVT, has a cash runway extended beyond 2027, with $221.8 million in cash, cash equivalents, and marketable securities.
The market capitalization of $TSVT is expected to increase significantly, with one analyst predicting a valuation of $25, five times the current market capitalization of $200 million.

Generated by AI

Recently published CAR T-Cell Therapy for NHL Market Insights report includes a comprehensive understanding of current treatment practices, CAR T-cell therapy for NHL emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

2mo agoYahoo Finance

Also Discussed

Investors talking about TSVT also mention

#	Name	Attention
1	BLUE - bluebird bio, Inc.	——
2	CRISPR Therapeutics AGCRSP	0%0
3	Beam Therapeutics IncBEAM	0.02%+0.02
4	Legend Biotech Corporation ADRLEGN	0%+0
5	Editas Medicine, Inc.EDIT	0%+0
6	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
7	uniQure N.V.QURE	0.02%+0.01
8	Allogene Therapeutics IncALLO	0%new
9	OCFT - OneConnect Financial Technology Co., Ltd.	——
10	Bristol-Myers Squibb CompanyBMY	0.01%0

2seventy bio, Inc.

Location

Social

What share of all stock conversation is about TSVT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 13

Insider Kynam Global Healthcare Master Fund, LP sold 16,238,047 shares of $TSVT, valued at $80M.
This trade represents a 100% reduction in the fund's position in 2Seventy Bio, Inc.
The sale was made at $4.93 per share.

Generated by AI

Sentiment

Of the messages about TSVT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +43.05
Bearish	—	—	—	0% -43.05

Bullish· Mar 11

$TSVT is being acquired by Bristol Myers Squibb in an all-cash deal valued at approximately $286 million, representing an 88% premium to its current price.
The acquisition is a significant win for biotech bulls, signaling strong value in the sector and driving momentum for the stock.
The deal is expected to provide significant value to shareholders, with the stock price surging over 76% in pre-market trading.

Bearish· Mar 11

$TSVT was acquired by BMS for a low price of $5 per share, with a total deal value of $102M net of cash.
The acquisition is considered a terrible deal for shareholders, with BMS paying only 85% of 1 year of TSVT's sales share.
The combined value of TSVT and BLUE has collapsed, with the two companies being sold for a total of $300M, down from a peak of $9B.

Generated by AI

Topics

Of the messages about TSVT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	24%
Announcements	—	—	—	42%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	34%

Analysts· Nov 8

Morgan Stanley initiated coverage on 2seventy bio (TSVT) with an Overweight rating and a price target of $72.
Several analysts have downgraded bluebird bio (TSVT), including Goldman Sachs to Sell with a price target of $10, and Morgan Stanley to Underweight with a price target of $11.
Analysts have also reduced price targets for bluebird bio (TSVT), including Wedbush to $11, Canaccord Genuity to $15, Wells Fargo to $16, Barclays to $13, and Royal Bank of Canada to $14.

Announcements· Mar 11

2seventy bio, Inc. (TSVT) has entered into a definitive agreement to be acquired by Bristol Myers Squibb (BMY) in an all-cash transaction valued at approximately $286 million.
The acquisition price is $5.00 per share, representing an 88% premium to the closing price of $2.66 on March 7, 2025.
The deal is expected to close in the second quarter of 2025, subject to customary closing conditions.

Controversies· Feb 16

bluebird bio, the company behind 2seventy bio's gene therapy, has temporarily suspended its Phase 1/2 and Phase 3 studies of LentiGlobin gene therapy for sickle cell disease due to a second case of cancer in a patient.
A lawsuit has been filed against bluebird bio and its executives for allegedly violating federal securities laws, citing concerns over the safety of the company's gene therapy.
The temporary suspension of bluebird bio's gene therapy studies and the resulting regulatory scrutiny are expected to negatively impact other companies in the gene therapy space, including 2seventy bio.

Technical Analysis· Dec 10

$TSVT broke out of a descending bear channel and re-tested it as support with a huge expansion bullish engulfing candle, adding to its watch list and looking to buy a low-volume pullback.
$TSVT has crossed its 6-month MA, indicating a potential 10-dollar move from here, and is currently above its 50-day MA, which acted as significant resistance in the past.
A close above $77.47 on the 30-minute chart would confirm a cup and handle setup, while a close above yesterday's high would be a good sign, indicating potential for a reversal.

Generated by AI

Community

Of the messages about TSVT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	60.22%
Newcomers	—	—	—	39.78%

Regulars· Apr 5

The FDA has approved Abecma, a treatment for relapsed or refractory multiple myeloma, which is a significant development for 2seventy bio, Inc. ($TSVT) and its partner Bristol Myers Squibb ($BMY).
Analysts estimate $601M in sales for Abecma in 2024, according to LSEG data, which could have a positive impact on $TSVT's stock price.
Some investors are speculating about a potential buyout from Bristol Myers Squibb, with one user expecting a buyout to happen soon.

Newcomers· Mar 18

$TSVT has received a positive FDA Advisory Committee vote for its Abecma treatment, with an 8-3 vote in favor of its favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma.
2seventy bio, the parent company of $TSVT, has a cash runway extended beyond 2027, with $221.8 million in cash, cash equivalents, and marketable securities.
The market capitalization of $TSVT is expected to increase significantly, with one analyst predicting a valuation of $25, five times the current market capitalization of $200 million.

Generated by AI

2seventy bio

Social

Mar 13

Sentiment

Bullish· Mar 11

Bearish· Mar 11

Topics

Analysts· Nov 8

Announcements· Mar 11

Controversies· Feb 16

Technical Analysis· Dec 10

Community

Regulars· Apr 5

Newcomers· Mar 18

News

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

Also Discussed

2seventy bio, Inc.

Company Information

Location

News

CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

Also Discussed

Social

Mar 13

Sentiment

Bullish· Mar 11

Bearish· Mar 11

Topics

Analysts· Nov 8

Announcements· Mar 11

Controversies· Feb 16

Technical Analysis· Dec 10

Community

Regulars· Apr 5

Newcomers· Mar 18